DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073–86.

Article  CAS  PubMed  Google Scholar 

San Jose-Eneriz E, Gimenez-Camino N, Rabal O, Garate L, Miranda E, Gomez-Echarte N, et al. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia. Nat Commun. 2024;15:5570.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thol F, Dohner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143:11–20.

Article  CAS  PubMed  Google Scholar 

Jayavelu AK, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. 2022;40:301–17.e12.

Article  CAS  PubMed  Google Scholar 

Stratmann S, Vesterlund M, Umer HM, Eshtad S, Skaftason A, Herlin MK, et al. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia. 2023;37:550–9.

Article  CAS  PubMed  Google Scholar 

Li JF, Cheng WY, Lin XJ, Wen LJ, Wang K, Zhu YM, et al. Aging and comprehensive molecular profiling in acute myeloid leukemia. Proc Natl Acad Sci USA. 2024;121:e2319366121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14:49.

Article  PubMed  PubMed Central  Google Scholar 

Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108:308–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barajas JM, Rasouli M, Umeda M, Hiltenbrand R, Abdelhamed S, Mohnani R, et al. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. Blood. 2024;143:619–30.

Article  CAS  PubMed  Google Scholar 

Decroocq J, Birsen R, Montersino C, Chaskar P, Mano J, Poulain L, et al. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia. 2022;36:1237–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Droegemeier K, Baselga J, Fouse J. BCL2/MDM2 inhibitor combo effective in AML. Cancer Discov. 2019;9:156.

Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017;32:748–60.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022;139:907–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.

Li JB, Levanon EY, Yoon JK, Aach J, Xie B, Leproust E, et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science. 2009;324:1210–3.

Article  CAS  PubMed  Google Scholar 

Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol. 2016;17:83–96.

Article  CAS  PubMed  Google Scholar 

Song B, Shiromoto Y, Minakuchi M, Nishikura K. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdiscip Rev RNA. 2022;13:e1665.

Article  CAS  PubMed  Google Scholar 

Baker AR, Slack FJ. ADAR1 and its implications in cancer development and treatment. Trends Genet. 2022;38:821–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shigeyasu K, Okugawa Y, Toden S, Miyoshi J, Toiyama Y, Nagasaka T, et al. AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. JCI Insight. 2018;3(12):e99976.

Luo J, Gong L, Yang Y, Zhang Y, Liu Q, Bai L, et al. Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in hepatocellular carcinoma. Hepatology. 2024;79:61–78.

Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 2018;132:1304–17.

Article  CAS  PubMed  Google Scholar 

Jiang Q, Isquith J, Zipeto MA, Diep RH, Pham J, Delos Santos N, et al. Hyper-editing of cell-cycle regulatory and tumor suppressor RNA promotes malignant progenitor propagation. Cancer Cell. 2019;35:81–94.e7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiao Y, Xu Y, Liu C, Miao R, Liu C, Wang Y, et al. The role of ADAR1 through and beyond its editing activity in cancer. Cell Commun Signal. 2024;22(1):42.

Meduri E, Breeze C, Marando L, Richardson SE, Huntly BJP. The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome. iScience. 2022;25:105622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiao H, Cheng Q, Wu X, Tang Y, Liu J, Li X. ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway. Cancer Manag Res. 2019;11:8547–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.

Article  CAS  PubMed  Google Scholar 

Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: a promising therapeutic target in cancer. Int J Mol Sci. 2022;23(19):11502.

Cho C, Myung S-J, Chang S. ADAR1 and MicroRNA, a hidden crosstalk in cancer. Int J Mol Sci. 2017;18(4):799.

Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, et al. ADAR1 activation drives leukemia stem cell self-renewal by impairing let-7 biogenesis. Cell Stem Cell. 2016;19:177–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Xu X, Yu S, Jeong KJ, Zhou Z, Han L, et al. Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. Genome Res. 2017;27:1112–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang S, Chen H, Liu W, Fang L, Qian Z, Kong R, et al. miR-766-3p targeting BCL9L suppressed tumorigenesis, epithelial-mesenchymal transition, and metastasis through the beta-catenin signaling pathway in osteosarcoma cells. Front Cell Dev Biol. 2020;8:594135.

Article  PubMed  PubMed Central  Google Scholar 

You Y, Que K, Zhou Y, Zhang Z, Zhao X, Gong J, et al. MicroRNA-766-3p inhibits tumour progression by targeting Wnt3a in hepatocellular carcinoma. Mol Cells. 2018;41:830–41.

CAS  PubMed  PubMed Central  Google Scholar 

Chen T, Xiang JF, Zhu SS, Chen SY, Yin QF, Zhang XO, et al. ADAR1 is required for differentiation and neural induction by regulating microRNA processing in a catalytically independent manner. Cell Res. 2015;25:459–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quick-Cleveland J, Jacob JP, Weitz SH, Shoffner G, Senturia R, Guo F. The DGCR8 RNA-binding heme domain recognizes primary microRNAs by clamping the hairpin. Cell Rep. 2014;7:1994–2005.

Article  CAS  PubMed